<p>Patient preferences for glucagon-like peptide-1 receptor&ndash;agonist treatment attributes</p>

Abstract

Purpose The importance of patient-centered care in the management of type 2 diabetes mellitus (T2DM) is widely advocated. Understanding the attributes of T2DM medications important to patients is thus essential for effective management, in order to limit disease progression. This literature review aimed to identify studies comparing patient preferences, based on process and outcome attributes, between GLP1-receptor agonist (RA) profiles and between GLP1 RA and insulin profiles. Methods MEDLINE, Embase, PsycINFO, and the Cochrane Library (2005–present) were searched for studies in patients with T2DM or the general population that compared preferences for GLP1 RAs or GLP1 RAs versus insulin using contingent valuation, conjoint analysis (discrete-choice experiments [DCEs], willingness to pay), rating-based approaches of specific attributes, standard gamble, or time trade-off. Studies comparing drug A versus drug B without explicit attribute valuation were excluded. Results Ten records met eligibility criteria. Eight studies compared preferences for GLP1 RA– profile attributes, one compared GLP1 RA versus insulin glargine profiles, and one addressed both comparisons. Important attributes driving patient preferences in DCEs were dose frequency, type of device, needle size, change in glycated hemoglobin, and adverse-event profile. Time trade-off evaluations demonstrated that weekly GLP1 RA injection-device attributes (reconstitution, waiting during preparation, needle handling) had a measurable impact on preference. Willingness-to-pay analysis showed that patients were more willing to pay extra for attributes of once-daily liraglutide over twice-weekly exenatide or insulin. Direct preference elicitation in DCEs revealed that patients preferred medication profiles representing GLP1 RAs with less frequent dosing and preferred GLP1 RA profiles over insulin. Conclusion Process and outcome attributes are important drivers of patient preference for GLP1 RAs. Findings from patient-preference studies can inform clinical decision-making and help align care with patient values, which has the potential to improve medication adherence and outcomes.

Patients’ preferences for health insurance coverage of new technologies for treating chronic diseases in China: a discrete choice experiment

“…Due to differences in nature and characteristics of the disease, the results may not represent the preferences of patients with other types of chronic diseases. Although prior DCEs [44][45][46][47][48] made conclusions that were similar to ours in terms of the relative importance of technology attributes regarding benefits and risks. Future studies need to enrol patients with other diseases and conduct subgroup analyses to identify variations in patients' preferences across different types of diseases.…”

“…Comparison with other studies Our findings of patients valuing the effectiveness and safety of medical technologies were consistent with the results by prior studies from other countries which aimed to investigate patients' preferences for the treatment of chronic diseases. [44][45][46][47][48] Our study confirmed that new technologies that could increase health benefits and minimise potential risks were preferred by patients.…”

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

“…A growing body of literature has examined patient preferences among glucagon‐like peptide‐1 (GLP‐1) receptor agonists, which are often recommended for glycaemic control in patients with T2D . Medications in this class have been shown to have efficacy for lowering HbA1c with a low risk of hypoglycaemia and a potential benefit of weight loss .…”

“…[35][36][37][38] Attributes of the injection device and procedures that have been shown to contribute to patient preference include needle handling requirements, steps for preparing the injection device, dose frequency and overall ease of use. 10,[39][40][41][42] The dulaglutide and semaglutide injection devices have been compared in a previous study in which preferences were based on descriptions of the devices with images from the device instructions for use, rather than actual experience of using the devices. 43 The primary objective of the current study was to examine preference between the dulaglutide and semaglutide injection devices after participants had been trained to inject with both devices and then used them to administer injections into an injection pad.…”

GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date

“…Suboptimal adherence and persistence across the GLP-1RA class may be attributed to a variety of factors of importance to both patients and prescribers, including frequency of injections, administration device, needle size, efficacy, gastrointestinal side effects, and safety [106], as well as the more general consideration of affordability [107]. Although the variation across this class does allow for individualization of treatment for people with T2D, prescribers are faced with the challenge of familiarizing themselves with the dosing regimens and devices for several agents, with limited time and resources to educate patients on the correct administration and titration of these medications [68,108].…”